{"id":987880,"date":"2026-07-31T07:33:39","date_gmt":"2026-07-31T11:33:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-receives-uae-department-of-health-doh-authorization-to-proceed-with-novel-prospective-genomics-guided-precision-medicine-study-evaluating-teverelix-in-women-with-endometriosis\/"},"modified":"2026-07-31T07:33:39","modified_gmt":"2026-07-31T11:33:39","slug":"medicus-pharma-receives-uae-department-of-health-doh-authorization-to-proceed-with-novel-prospective-genomics-guided-precision-medicine-study-evaluating-teverelix-in-women-with-endometriosis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-receives-uae-department-of-health-doh-authorization-to-proceed-with-novel-prospective-genomics-guided-precision-medicine-study-evaluating-teverelix-in-women-with-endometriosis\/","title":{"rendered":"Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix\u00ae in Women with Endometriosis"},"content":{"rendered":"

\nRandomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women’s health
\n<\/h2>\n
\n

PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the United Arab Emirates (UAE) Department of Health \u2013 Abu Dhabi (“DOH”) has granted Investigational New Drug (“IND”) authorization for the Company’s PRECISION-E2<\/strong>\u00a0Phase 2a clinical study evaluating\u00a0Teverelix\u00ae<\/strong>\u00a0in women with moderate-to-severe symptomatic endometriosis, a chronic estrogen-dependent inflammatory disease that affects approximately one in ten women of reproductive age worldwide.<\/p>\n

The authorization follows completion of the DOH’s comprehensive scientific and regulatory review of the Company’s chemistry, manufacturing and controls (CMC), non-clinical, clinical and safety documentation and approved the \u201cStudy to Proceed\u201d<\/strong>, subject to completion of required site-specific Institutional Review Board (“IRB”) and ethics approvals.<\/p>\n

The\u00a0PRECISION-E2\u00a0study represents a significant regulatory milestone in Medicus’ women’s health strategy and advances the development of\u00a0Teverelix\u00ae\u00a0into what the Company believes is\u00a0one of the first prospective genomics-guided precision medicine development programs designed to identify women with moderate-to-severe endometriosis most likely to benefit from a long-acting GnRH antagonist.<\/p>\n

\n “Today’s IND authorization represents far more than approval to initiate another clinical study,\u201d <\/em>
\n
\n stated Dr. Raza Bokhari, Medicus Executive Chairman and CEO,<\/em>
\n <\/strong>
\n “it validates a development strategy designed to combine precision endocrinology, pharmacology and population genomics within a prospective clinical trial. We believe PRECISION-E2 has the potential not only to optimize the future development of Teverelix\u00ae but also is an important step toward personalized therapy that could help redefine how women with endometriosis and other estrogen-driven diseases are stratified and may support future development across multiple women’s health indications.\u201d<\/em>\n <\/p>\n

\n PRECISION-E2 Study Design:<\/strong>\n <\/p>\n

PRECISION-E2 (Precision Estradiol Suppression and Genomic Response Study in Endometriosis) is a prospective, randomized, placebo-controlled Phase 2a clinical study designed to evaluate the pharmacodynamics, safety, tolerability, clinical activity and exploratory genomic correlates of Teverelix\u00ae in approximately 84 women with moderate-to-severe symptomatic endometriosis across multiple investigational sites in the United Arab Emirates.\u00a0<\/p>\n

Participants will be randomized equally among four treatment groups:<\/p>\n